|
1
|
Fukuda R, Zhang H, Kim JW, et al: HIF-1
regulates cytochrome oxidase subunits to optimize efficiency of
respiration in hypoxic cells. Cell. 129:111–122. 2007.
|
|
2
|
Hirota K and Semenza GL: Regulation of
angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol.
59:15–26. 2006.
|
|
3
|
Kilic M, Kasperczyk H, Fulda S and Debatin
KM: Role of hypoxia inducible factor-1 alpha in modulation of
apoptosis resistance. Oncogene. 26:2027–2038. 2007.
|
|
4
|
Esteban MA, Tran MG, Harten SK, et al:
Regulation of E-cadherin expression by VHL and hypoxia-inducible
factor. Cancer Res. 66:3567–3575. 2006.
|
|
5
|
Li J, Shi M, Cao Y, et al: Knockdown of
hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells
results in reduced tumor growth and increased sensitivity to
methotrexate. Biochem Biophys Res Commun. 342:1341–1351. 2006.
|
|
6
|
Huang LE, Gu J, Schau M and Bunn HF:
Regulation of hypoxia-inducible factor 1alpha is mediated by an
O2-dependent degradation domain via the ubiquitin-proteasome
pathway. Proc Natl Acad Sci USA. 95:7987–7992. 1998.
|
|
7
|
Stiehl DP, Jelkmann W, Wenger RH and
Hellwig-Bürgel T: Normoxic induction of the hypoxia-inducible
factor 1alpha by insulin and interleukin-1beta involves the
phosphatidylinositol 3-kinase pathway. FEBS Lett. 512:157–162.
2002.
|
|
8
|
Semenza G: Signal transduction to
hypoxia-inducible factor 1. Biochem Pharmacol. 64:993–998.
2002.
|
|
9
|
Bárdos JI and Ashcrof M: Negative and
positive regulation of HIF-1: a complex network. Biochim Biophys
Acta. 1755:107–120. 2005.
|
|
10
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835. 1999.
|
|
11
|
Maxwell PH, Pugh CW and Ratcliffe PJ:
Activation of the HIF pathway in cancer. Curr Opin Genet Dev.
11:293–299. 2001.
|
|
12
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003.
|
|
13
|
Semenza GL: Hypoxia-inducible factors:
mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012.
|
|
14
|
Chen J, Zhao S, Nakada K, et al:
Dominant-negative hypoxia-inducible factor-1 alpha reduces
tumorigenicity of pancreatic cancer cells through the suppression
of glucose metabolism. Am J Pathol. 162:1283–1291. 2003.
|
|
15
|
Perrot-Applanat M and Di Benedetto M:
Autocrine functions of VEGF in breast tumor cells: adhesion,
survival, migration and invasion. Cell Adh Migr. 6:547–553.
2012.
|
|
16
|
Elliott S and Sinclair AM: The effect of
erythropoietin on normal and neoplastic cells. Biologics.
6:163–189. 2012.
|
|
17
|
Zheng H, Fu G, Dai T and Huang H:
Migration of endothelial progenitor cells mediated by stromal
cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal
transduction pathway. J Cardiovasc Pharmacol. 50:274–280. 2007.
|
|
18
|
Merseburger AS, Bellmunt J, Jenkins C, et
al: Perspectives on treatment of metastatic castration-resistant
prostate cancer. Oncologist. 18:558–567. 2013.
|
|
19
|
Zhang P, Wang Y, Hui Y, et al: Inhibition
of VEGF expression by targeting HIF-1alpha with small interference
RNA in human RPE cells. Ophthalmologica. 221:411–417. 2007.
|
|
20
|
Melillo G: Inhibiting hypoxia-inducible
factor 1 for cancer therapy. Mol Cancer Res. 4:601–605. 2006.
|
|
21
|
Jensen RL, Ragel BT, Whang K and Gillespie
D: Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha)
decreases vascular endothelial growth factor (VEGF) secretion and
tumor growth in malignant gliomas. J Neurooncol. 78:233–247.
2006.
|
|
22
|
Stoeltzing O, McCarty MF, Wey JS, et al:
Role of hypoxia-inducible factor 1alpha in gastric cancer cell
growth, angiogenesis, and vessel maturation. J Natl Cancer Inst.
96:946–956. 2004.
|
|
23
|
Brown LM, Cowen RL, Debray C, et al:
Reversing hypoxic cell chemoresistance in vitro using genetic and
small molecule approaches targeting hypoxia inducible factor-1. Mol
Pharmacol. 69:411–418. 2006.
|
